Female Hypoactive Sexual Desire Disorder – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Female Hypoactive Sexual Desire Disorder – Drugs In Development, 2024 report and make more profitable business decisions.
Hypoactive sexual desire disorder (HSDD) is an absence of sexual fantasies and desire for sexual activity. The predisposing factors include anxiety, depression, androgen deficiencies, and chronic debilitating illnesses such as chronic renal failure, hyper-prolactinaemia, and hypo-hyperthyroid states. Treatment includes antidepressant and hormone therapy.
The Female Hypoactive Sexual Desire Disorder drugs in development market research report provide comprehensive information on the therapeutics under development for Female Hypoactive Sexual Desire Disorder, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Female Hypoactive Sexual Desire Disorder and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Female Hypoactive Sexual Desire Disorder | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 9 molecules, with 9 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Female Hypoactive Sexual Desire Disorder therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Female Hypoactive Sexual Desire Disorder pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Female Hypoactive Sexual Desire Disorder treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Cosette Pharmaceuticals IncDare Bioscience Inc
Freya Pharma Solutions BV
Kuhnil Pharmaceutical Co Ltd
Palatin Technologies Inc
S1 Biopharma Inc
Shanghai Fosun Pharmaceutical (Group) Co Ltd
Viramal Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Female Hypoactive Sexual Desire Disorder reports